- Investors either weren't impressed with what they heard from management regarding Afrezza on MannKind's (MNKD -9.6%) Wednesday evening conference call or traders are simply taking some profits after yesterday's rally, as shares are down sharply in morning action.
- The company discussed results of the Affinity trials yesterday after the close, addressing a number of points including partnership plans and an apparent discrepancy between the previously specified between-group A1c difference (0.5%) and the observed difference (0.4%). As for the latter issue, the company says the P-value of .0001 leaves no doubt as to an "unequivocal superiority conclusion." (transcript)
- Merrill Lynch reportedly says Afrezza's potential as a complement to oral in the Type 2 market is uncertain.